( --------------------- Weekly 900 m...)AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting,Health

--------------------- Weekly 900 mg or less Weekly 1200 mg or 1500 mg ------------------------------------------------------------------------- Loading Dose 900 mg or less Loading Dose 1200 mg or more ------------------------------------------------------------------------- Daily Dose 100 mg or less Daily Dose 150 mg or more -------------------------------------------------------------------------

The dose schedules in the Phase 1 trials were weekly 100-800 mg or loading dose (LD) 300-1800 mg on Day 1 followed by 50-150 mg daily for Days 2-21 every 28 days or LD 400-900 mg & daily 50-100 mg continuously.

In the Phase 2 trials, doses were LD 900 mg Day 1 & 150 mg daily for days 2-21 every 28 days; LD 900 mg and 100 mg daily continuously; 50 mg daily continuously without a LD; and 900-1500 mg weekly. LD was reduced for cycle 2+ of the 28 day regimens.

Results

145 patients with sarcoma were entered on studies prior to December 31, 2006 and were assessed for CBR. Partial responses were seen, in one patient each, with chondrosarcoma, extra-skeletal myxoid chondrosarcoma, leiomyosarcoma and a desmoid tumor.

At lower doses with 52 patients fully evaluable for CBR, the CBR was 52% with 4 partial responses and 23 stable disease at >= 4 months.

At higher doses with 30 patients fully evaluable for CBR, the CBR was 53% with 16 stable disease at >= 4 months.

Toxicities were mainly gastrointestinal and/or fatigue. The percentage of patients with grade 0 nausea (N), vomiting (V), diarrhea (D) and fatigue (F) for lower dose perifosine (76 patients) was 46, 49, 38 and 55% respectively compared to 26, 32, 20 and 58 percent for higher dose perifosine (69 patients). The proportion of patients with grade 2+ N, V, D and F was 20, 13, 15 and 21% for lower dose perifosine and 49, 35, 42 and 25% for higher dose perifosine.

    Conclusions


    - Perifosin
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors
and In Vivo Results for a GHRH Antagonist at the AACR Annual
Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH
for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K

Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase
2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer
Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results
of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys
Investigational Drug to Treat Cocaine and Methamphetamine Addiction